Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 12/20 | 0.67 |
| ▸ | RARB | P10826 | 12/20 | 0.67 |
| ▸ | RARG | P13631 | 11/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.51 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444486 | 0.96 | RARA (0.73) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL18775415 | 0.86 | RARA (0.63) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL10246895 | 0.84 | RARB (0.64) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL17327788 | 0.84 | RARA (0.67) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL15070047 | 0.82 | RARA (0.68) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL17327701 | 0.82 | RARA (0.68) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL17316107 | 0.82 | RARA (0.54) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL17327720 | 0.82 | RARA (0.54) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL17327718 | 0.81 | HDAC6 (0.60) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL2331952 | 0.81 | RARB (1.00) | RARARARBRARGCYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152190-B1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC (US) | 2024-07-31 | — | — | EP | disclosed |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10752591-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752591-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180362467-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2018-12-20 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015188015-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752591-B2 | 18-20 member bi-polycyclic compounds | TNNI3, TNNC1, MYLK2 | RARA 4139/4885RARB 3587/4885RARG 4129/4885 |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | CKMT1A; CKMT1B, MYLK2, CPT1B | RARA 1809/4885RARB 1026/4885RARG 845/4885 |
| US-20180362467-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | CKMT1A; CKMT1B, MYLK2, CPT1B | RARA 1809/4885RARB 1026/4885RARG 845/4885 |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | BRCA1, UGT2B17, TP53 | RARA 1079/4885RARB 1128/4885RARG 862/4885 |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | CKMT1A; CKMT1B, MYLK2, CPT1B | RARA 1809/4885RARB 1026/4885RARG 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.